X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com/news-release/2024/03/10/2843436/0/en/Arcutis-Presents-Late-Breaking-Data-From-INTEGUMENT-PED-Phase-3-Trial-of-Roflumilast-Cream-0-05-in-Atopic-Dermatitis-in-Children-Ages-2-to-5-at-the-American-Academy-of-Dermatology-.html
https://www.globenewswire.com//news-release/2024/02/28/2837387/0/en/Arcutis-and-Sato-Announce-Strategic-Collaboration-and-Licensing-Agreement-for-Topical-Roflumilast-in-Japan.html
https://www.globenewswire.com/news-release/2024/01/29/2818829/0/en/Journal-of-the-American-Academy-of-Dermatology-Publishes-ZORYVE-roflumilast-Foam-0-3-Results-for-Seborrheic-Dermatitis-from-Pivotal-Phase-3-Trial.html
https://www.globenewswire.com//news-release/2024/01/22/2813014/0/en/ZORYVE-roflumilast-Topical-Foam-0-3-for-the-Treatment-of-Seborrheic-Dermatitis-Launches-in-the-United-States.html
https://www.globenewswire.com/news-release/2024/01/14/2808884/0/en/ZORYVE-Roflumilast-Topical-Foam-0-3-Clears-Seborrheic-Dermatitis-in-Individuals-Who-Previously-Reported-an-Inadequate-Response-to-Topical-Steroids.html
https://www.globenewswire.com/news-release/2024/01/14/2808885/0/en/Majority-of-Individuals-with-Atopic-Dermatitis-Improved-with-Arcutis-Roflumilast-Cream-0-15-According-to-New-Data-from-Phase-3-Program.html
https://www.fiercepharma.com/pharma/arcutis-zoryve-bags-second-fda-nod-time-foam-form-treat-seborrheic-dermatitis
https://www.globenewswire.com//news-release/2023/11/29/2787702/0/en/FDA-Accepts-Arcutis-Supplemental-New-Drug-Application-for-Roflumilast-Cream-0-15-for-the-Treatment-of-Atopic-Dermatitis-in-Adults-and-Children-Down-to-Age-6.html
https://www.globenewswire.com//news-release/2023/10/20/2763969/0/en/New-Data-Shows-ZORYVE-Roflumilast-Cream-0-3-Provided-Measurable-Improvement-of-Plaque-Psoriasis-in-Nearly-All-Individuals-in-DERMIS-Trials.html
https://www.globenewswire.com//news-release/2023/09/19/2745482/0/en/Arcutis-Announces-Positive-Results-from-INTEGUMENT-PED-Pivotal-Phase-3-Trial-of-Roflumilast-Cream-0-05-for-the-Treatment-of-Atopic-Dermatitis-in-Children-Ages-2-to-5.html
https://www.globenewswire.com//news-release/2023/09/12/2741541/0/en/Arcutis-Submits-Roflumilast-Cream-0-15-Supplemental-New-Drug-Application-to-the-FDA-for-the-Treatment-of-Atopic-Dermatitis-in-Adults-and-Children-Ages-6-Years-and-Older.html
https://www.globenewswire.com//news-release/2023/09/07/2739327/0/en/Arcutis-Announces-Positive-Long-Term-Results-of-Roflumilast-Cream-0-15-Showing-Durable-and-Improved-Efficacy-Over-Time-and-Favorable-Safety-Profile-in-Treatment-of-Mild-to-Moderate.html
https://www.globenewswire.com/news-release/2023/08/10/2722655/0/en/Arcutis-and-Huadong-Announce-Strategic-Collaboration-and-Licensing-Agreement-for-Topical-Roflumilast-in-Greater-China-and-Southeast-Asia.html
https://www.globenewswire.com/news-release/2023/07/17/2705601/0/en/Arcutis-Announces-ZORYVE-Roflumilast-Cream-0-3-Has-Been-Included-in-a-Preferred-Position-on-National-Formularies-for-CVS-Caremark.html
https://www.arcutis.com/arcutis-announces-first-quarter-2023-financial-results-and-provides-business-update/
https://www.globenewswire.com/news-release/2023/05/02/2659096/0/en/Arcutis-Completes-Enrollment-in-INTEGUMENT-PED-Pivotal-Phase-3-Trial-of-Roflumilast-Cream-0-05-for-the-Treatment-of-Atopic-Dermatitis-in-Children-Ages-2-to-5.html
https://www.arcutis.com/arcutis-announces-canadian-approval-of-zoryve-roflumilast-cream-0-3-for-treatment-of-plaque-psoriasis-in-individuals-12-years-and-older/
https://www.tribuneindia.com/news/nation/zydus-lifesciences-gets-final-usfda-approval-to-manufacture-generic-anti-inflammation-drug-498922
https://www.globenewswire.com/news-release/2023/04/18/2648950/0/en/Arcutis-Announces-FDA-Acceptance-of-New-Drug-Application-for-Roflumilast-Foam-0-3-for-the-Treatment-of-Seborrheic-Dermatitis-in-Individuals-Aged-9-Years-and-Older.html
https://www.globenewswire.com/news-release/2023/04/05/2641616/0/en/Arcutis-Announces-New-Coverage-for-ZORYVE-Roflumilast-Cream-0-3-with-National-and-Regional-Health-Plan-Formularies-Bringing-Total-Commercial-Covered-Lives-to-Over-110-Million.html
https://www.globenewswire.com/news-release/2023/03/09/2624043/0/en/Arcutis-to-Present-New-Topical-Roflumilast-Data-Including-Late-Breaking-Atopic-Dermatitis-Pivotal-Trial-Data-During-the-American-Academy-of-Dermatology-AAD-Annual-Meeting.html
https://www.clinicaltrialsarena.com/news/arcutis-roflumilast-cream-trial/
https://www.globenewswire.com/news-release/2022/12/19/2576249/0/en/Arcutis-Submits-Supplemental-New-Drug-Application-for-ZORYVE-roflumilast-Cream-0-3-for-Expanded-Indication-for-the-Treatment-of-Plaque-Psoriasis-in-Children-Down-to-2-Years-of-Age.html
https://www.biospace.com/article/releases/arcutis-announces-positive-topline-results-from-second-atopic-dermatitis-pivotal-phase-3-trial-of-roflumilast-cream-in-adults-and-children-aged-6-and-older/?s=63
https://www.globenewswire.com//news-release/2022/12/12/2571826/0/en/Arcutis-Announces-Positive-Topline-Results-from-Second-Atopic-Dermatitis-Pivotal-Phase-3-Trial-of-Roflumilast-Cream-in-Adults-and-Children-Aged-6-and-Older.html
https://www.globenewswire.com/news-release/2022/11/17/2558146/0/en/Arcutis-ZORYVE-Roflumilast-Cream-0-3-Added-to-Express-Scripts-Inc-National-Formularies-in-the-United-States.html
https://www.globenewswire.com/news-release/2022/11/15/2556479/0/en/CORRECTION-Arcutis-Announces-Positive-Topline-Results-from-INTEGUMENT-1-Pivotal-Phase-3-Trial-of-Roflumilast-Cream-in-Atopic-Dermatitis-in-Adults-and-Children-Aged-Six-Years-and-Ol.html
https://www.globenewswire.com/news-release/2022/11/15/2556071/0/en/Arcutis-Announces-Positive-Topline-Results-from-INTEGUMENT-1-Pivotal-Phase-3-Trial-of-Roflumilast-Cream-in-Atopic-Dermatitis-in-Adults-and-Children-Aged-Six-Years-and-Older.html
https://www.globenewswire.com/news-release/2022/09/26/2522479/0/en/Arcutis-Announces-Positive-Topline-Results-from-ARRECTOR-Pivotal-Phase-3-Trial-of-Roflumilast-Foam-0-3-in-Scalp-and-Body-Psoriasis.html
https://www.globenewswire.com/news-release/2022/09/20/2519470/0/en/Journal-of-the-American-Medical-Association-Publishes-Roflumilast-Cream-0-3-Results-from-Pivotal-DERMIS-1-and-2-Phase-3-Trials-in-Plaque-Psoriasis.html
https://www.globenewswire.com/news-release/2022/09/09/2513265/0/en/New-Data-from-Arcutis-STRATUM-Pivotal-Phase-3-Trial-of-Roflumilast-Foam-0-3-in-Seborrheic-Dermatitis-Presented-at-European-Academy-of-Dermatology-and-Venereology-EADV-Congress.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208256
https://www.arcutis.com/new-data-from-arcutis-topical-roflumilast-clinical-program-presented-at-the-european-academy-of-dermatology-and-venereology-eadv-congress/
https://www.fiercepharma.com/pharma/arcutis-psoriasis-cream-zoryve-clinches-win-seborrheic-dermatitis-trial-proving-its-no-one
https://www.globenewswire.com/news-release/2022/08/22/2502154/0/en/Arcutis-Announces-Arcutis-Cares-Patient-Assistance-Program-PAP-For-Financially-Qualified-Uninsured-and-Underinsured-Patients.html
https://www.fiercepharma.com/pharma/armed-570m-warchest-arcutis-launches-psoriasis-cream-us
https://www.globenewswire.com/news-release/2022/08/01/2489296/0/en/Arcutis-to-Host-Investor-Conference-Call-Today-to-Discuss-the-FDA-Approval-of-ZORYVE-roflumilast-Cream-0-3-for-Plaque-Psoriasis.html
https://endpts.com/arcutis-pulls-in-a-win-for-its-topical-version-of-an-old-astrazeneca-drug-in-plaque-psoriasis/
https://www.globenewswire.com/news-release/2022/07/11/2477212/0/en/Arcutis-Biotherapeutics-Announces-Health-Canada-Accepts-for-Review-the-New-Drug-Submission-for-Roflumilast-Cream-for-Adults-and-Adolescents-with-Plaque-Psoriasis.html
https://www.globenewswire.com/news-release/2022/06/06/2456603/0/en/Arcutis-Announces-Positive-Topline-Results-from-STRATUM-Pivotal-Phase-3-Trial-of-Roflumilast-Foam-0-3-in-Seborrheic-Dermatitis.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208299
https://www.globenewswire.com/news-release/2022/04/06/2417524/0/en/Arcutis-Completes-Enrollment-in-ARRECTOR-Pivotal-Phase-3-Trial-of-Topical-Roflumilast-Foam-in-Scalp-and-Body-Psoriasis.html
https://www.globenewswire.com/news-release/2022/03/25/2410168/0/en/Arcutis-Roflumilast-Foam-Demonstrates-Clinically-Meaningful-Results-and-Patient-Quality-of-Life-Improvements-in-Phase-2-Seborrheic-Dermatitis-Study.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-pharmaceuticals-usa-inc-gets-final-us-fda-approval-to-market-roflumilast-tablets/articleshow/89561891.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208303
https://www.fiercepharma.com/pharma/despite-strong-efficacy-dermatologist-survey-indicates-incyte-s-opzelura-may-have-difficulty
https://www.globenewswire.com/news-release/2021/10/04/2307854/0/en/Arcutis-Submits-Topical-Roflumilast-Cream-New-Drug-Application-to-FDA-for-the-Treatment-of-Adults-and-Adolescents-with-Plaque-Psoriasis.html
https://www.globenewswire.com/news-release/2021/10/04/2307854/0/en/Arcutis-Submits-Topical-Roflumilast-Cream-New-Drug-Application-to-FDA-for-the-Treatment-of-Adults-and-Adolescents-with-Plaque-Psoriasis.html
https://www.globenewswire.com/news-release/2021/09/27/2303582/0/en/New-Topical-Roflumilast-Data-Presented-at-the-European-Academy-of-Dermatology-and-Venereology-EADV-Congress.html
https://www.globenewswire.com/news-release/2021/08/25/2286281/0/en/Arcutis-Enrolls-First-Patient-in-Phase-3-Clinical-Trial-of-Topical-Roflumilast-Foam-ARQ-154-as-a-Potential-Treatment-for-Scalp-and-Body-Psoriasis.html
Market Place
Share 
